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Infl ammation of actinic keratoses 
with capecitabine therapy for colon cancer
Capecitabine is an orally administered systemic prodrug of 
5-ﬂ uorouracil (5-FU), currently used as an anti-neoplastic 
agent. Tumor-specifi c conversion to the active drug im-
proves tolerability and intra-tumor drug concentrations. It 
is currently approved for colorectal and breast cancer, and 
has been used either alone or in combination with other 
chemotherapy regimens [1].
Actinic keratoses are focal areas of abnormal keratinocyte 
proliferation and differentiation, presenting as keratotic 
lesions on chronically light-exposed skin. They are usual-
ly considered a premalignant lesion, with a low risk of 
progression to invasive squamous cell carcinoma. There 
is vast experience with topical use of 5-FU on actinic 
keratoses, with randomised controlled trials confi rming 
effi cacy [2, 3].
We describe a 67-year-old Caucasian male, with a 3-year 
history of rectal adenocarcinoma, with local recurrences 
treated with surgery and radiotherapy. Chemotherapy was 
started with capecitabine, 2,150 mg (1,250 mg/m2) twice 
daily for 2 weeks, followed by a 1 week rest period. Four 
days after starting capecitabine, the patient developed ar-
eas of inﬂ ammation on the scalp and face, and was sent for 
dermatological assessment. On examination, all inﬂ am-
matory aspects were restricted to areas of previous actinic 
keratoses, with erythema and localised pain (fi gure 1). The 
chemotherapy schedule was maintained, and after 8 weeks 
no remaining inﬂ ammatory activity was present, with 
complete clearing of the actinic keratoses.
After 6 weeks of therapy he also developed erythema and 
skin darkening on the palms and soles, with mild discom-
fort. This frequent side-effect of anti-neoplastic chemo-
therapies is called hand-foot syndrome or palmoplantar 
erythrodysesthesia, and 5-FU and derivates are the most 
often implicated agents [4].
Inﬂ ammation of actinic keratoses with the systemic use of 
capecitabine has very rarely been reported in the literature 
[5, 6]. It could be considered an almost expected side-effect, 
due to the effi cacy of topically applied 5-FU on actinic kera-
toses, and probably has been under-reported. It is important 
to recognise this reaction and advise patients with actinic 
keratoses of the potential inﬂ ammatory response, assuring 
them that it will be limited and may even be benefi cial. 
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Progressive nodular histiocytosis – 
A ﬁ ve-year follow up
Progressive nodular histiocytosis (PNH) was fi rst described 
as progressive nodular histiocytoma by Taunton et al. [1]. 
PNH is an extremely rare skin disorder which is belongs to 
the group of non-Langerhans cell histiocytosis. Clinically, 
the disease is characterized by the progressive appearance 
of widespread xanthomatous papules and nodules without 
showing spontaneous remission. The histological appear-
ance of the disease is related to juvenile xanthogranuloma 
(JXG). Herein, we report a 10-year-old girl who was fi rst 
diagnosed as JXG but, for 5 years, had had progressively 















Figure 1. A) and B) Inﬂ ammation restricted to areas of actinic 
keratoses; C) and D) Complete improvement, with resolution 
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